

# Junji Furuse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7498435/publications.pdf>

Version: 2024-02-01

88  
papers

5,616  
citations

126708

33  
h-index

82410

72  
g-index

92  
all docs

92  
docs citations

92  
times ranked

6197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatments for elderly cancer patients and reforms to social security systems in Japan. <i>International Journal of Clinical Oncology</i> , 2022, 27, 310-315.	1.0	9
2	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 77-90.	5.1	526
3	Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). <i>Oncologist</i> , 2021, 26, 97-e201.	1.9	2
4	Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 26-54.	1.4	112
5	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 1-25.	1.4	29
6	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 181-190.	2.3	20
7	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 317-324.	0.6	1
8	A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 2088-2099.	1.3	1
9	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. <i>Liver Cancer</i> , 2021, 10, 249-259.	4.2	49
10	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1185-1196.	0.6	8
11	Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2021, 11, 12885.	1.6	1
12	Systemic therapy for hepatocellular carcinoma: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1363-1371.	0.6	3
13	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 397-404.	1.1	5
14	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	1.2	16
15	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3759-3769.	1.7	29
16	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	15.2	209
17	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	1.8	254
18	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96

#	ARTICLE	IF	CITATIONS
19	Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. <i>Pancreatology</i> , 2020, 20, 1421-1427.	0.5	18
20	Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). <i>Pancreatology</i> , 2020, 20, 1183-1188.	0.5	6
21	nalâ€¦RI+5â€¦FU/LV versus 5â€¦FU/LV in postâ€¦gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. <i>Cancer Medicine</i> , 2020, 9, 9396-9408.	1.3	26
22	Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. <i>Pancreatology</i> , 2020, 20, 944-950.	0.5	14
23	Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 358-360.	4.2	21
24	Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society. <i>Pancreas</i> , 2020, 49, 326-335.	0.5	125
25	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. <i>Journal of Gastroenterology</i> , 2020, 55, 369-382.	2.3	48
26	Firstâ€¦inâ€¦human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. <i>Cancer Science</i> , 2020, 111, 571-579.	1.7	16
27	The 2019 revision of the Clinical Practice Guidelines for pancreatic cancer -General remarks. <i>Suizo</i> , 2020, 35, 40-46.	0.1	0
28	Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. <i>Journal of Clinical Medicine</i> , 2019, 8, 1170.	1.0	4
29	A multicenter, openâ€¦label, singleâ€¦arm study of anamorelin (ONOâ€¦7643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , 2019, 125, 4294-4302.	2.0	99
30	A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?. <i>EBioMedicine</i> , 2019, 40, 9-10.	2.7	2
31	Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan. <i>World Journal of Gastroenterology</i> , 2019, 25, 107-117.	1.4	13
32	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). <i>European Journal of Cancer</i> , 2019, 106, 78-88.	1.3	21
33	A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 317-321.	0.6	11
34	A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1017-1023.	1.1	103
35	Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 25, 261-268.	1.4	31
36	Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. <i>Cancer Science</i> , 2018, 109, 215-224.	1.7	39

#	ARTICLE	IF	CITATIONS
37	Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. <i>Cancer Science</i> , 2018, 109, 2549-2557.	1.7	48
38	An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 511-519.	1.1	25
39	Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. <i>Surgical Case Reports</i> , 2018, 4, 26.	0.2	7
40	Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). <i>Pancreatology</i> , 2018, 18, 841-845.	0.5	23
41	New developments in systemic therapy for advanced biliary tract cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 703-711.	0.6	64
42	Emerging protein kinase inhibitors for treating pancreatic cancer. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 77-86.	1.0	11
43	Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society. <i>Pancreas</i> , 2017, 46, 595-604.	0.5	116
44	Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. <i>Clinical Cancer Research</i> , 2017, 23, 4625-4632.	3.2	150
45	A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 512-519.	0.6	14
46	S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 407-417.	3.7	51
47	A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. <i>Anticancer Research</i> , 2017, 37, 909-914.	0.5	5
48	Familial pancreatic cancer: Concept, management and issues. <i>World Journal of Gastroenterology</i> , 2017, 23, 935.	1.4	81
49	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. <i>Journal of Gastroenterology</i> , 2016, 51, 1150-1160.	2.3	44
50	Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 595-603.	1.1	131
51	Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 193-193.	0.8	20
52	Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. <i>Cancer Science</i> , 2015, 106, 611-617.	1.7	21
53	A phase I/II study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1058-1067.	1.2	13
54	Microarray Analysis of Gene Expression at the Tumor Front of Colon Cancer. <i>Anticancer Research</i> , 2015, 35, 6577-81.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. <i>Cancer Science</i> , 2014, 105, 1321-1326.	1.7	156
56	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 57.	3.8	515
57	A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 354-354.	0.8	0
58	A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1141-1146.	1.1	51
59	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 2-7.	0.6	4
60	Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japanese multicenter clinical oncology group trial (JCOG 0805). <i>Cancer Science</i> , 2013, 104, 1211-1216.	1.7	99
61	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1640-1648.	0.8	548
62	A phase IIb study of GSK1120212 (trametinib) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, e20004-e20004.	0.8	0
63	Current status and future direction of chemotherapy for pancreatic cancer. <i>Chinese Clinical Oncology</i> , 2013, 2, 6.	0.4	3
64	Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 903-911.	0.6	47
65	Role of chemotherapy in treatments for biliary tract cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 337-341.	1.4	26
66	Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). <i>Journal of Clinical Oncology</i> , 2012, 30, 4031-4031.	0.8	3
67	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 37-51.	1.1	5
68	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 256-262.	5.1	356
69	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. <i>Cancer Science</i> , 2011, 102, 425-431.	1.7	51
70	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 31-39.	2.0	33
71	Inhibitor of MEK1/2, selumetinib, for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 579-581.	1.4	3
72	Targeted Therapy for Biliary Tract Cancer. <i>Cancers</i> , 2011, 3, 2243-2254.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. <i>Cancer Science</i> , 2010, 101, 2606-2611.	1.7	28
74	Randomized Phase II Study of Gemcitabine plus S-1 Combination Therapy vs. S-1 in Advanced Biliary Tract Cancer: Japan Clinical Oncology Group Study (JCOG0805). <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1189-1191.	0.6	13
75	Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 573-579.	0.6	63
76	Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. <i>Oncology</i> , 2010, 79, 39-45.	0.9	23
77	A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 113-120.	1.1	21
78	A late phase II study of S-1 for metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 615-621.	1.1	156
79	S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 849-855.	1.1	132
80	Guidelines for chemotherapy of biliary tract and ampullary carcinomas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 55-62.	2.0	59
81	Postoperative adjuvant treatments for biliary tract cancer. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 463-467.	2.0	8
82	Growth factors as therapeutic targets in HCC. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 8-15.	2.0	31
83	Sorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 779.	3.0	34
84	A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 843-851.	0.6	94
85	Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. <i>Cancer Science</i> , 2007, 99, 071113200242005-???	1.7	170
86	Early Phase II Study of Uracil-Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 552-556.	0.6	27
87	Chemotherapy in the Treatment of Advanced Gallbladder Cancer. <i>Oncology</i> , 2004, 66, 138-142.	0.9	30
88	Management of elderly patients with unresectable pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1